ArticleJAMA network open2026
Genomic Testing Uptake Among Medicare Beneficiaries With Cancer.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Genomic testing plays a central role in precision oncology by guiding targeted therapies. Medicare established national coverage determinations (NCDs) for next-generation sequencing (NGS) in 2018 and 2020, yet population-level adoption patterns remain underexamined. Objective: To examine trends and variation in uptake of NGS and non-NGS genomic testing among Medicare beneficiaries with common cancers. Design, Setting, and Participants: This retrospective cohort study used Medicare fee-for-service beneficiaries aged 66 years or older with claims from January 1, 2016, to December 31, 2023. Beneficiaries with incident lung, breast, colorectal, prostate, or endometrial cancer were identified using the Chronic Conditions Data Warehouse. The data analysis was performed from July 1 to December 31, 2025. Exposures: Cancer types, time periods defined by implementation of Medicare NCDs for somatic NGS (March 16, 2018) and germline NGS (January 27, 2020), and patient characteristics (age, race and ethnicity, and geographic location). Main Outcomes and Measures: Outcomes were receipt of NGS testing (primary) and receipt of any genomic testing and shift to NGS testing among tested beneficiaries (secondary), within 180 days after the first cancer diagnosis claim. Testing rates were described by cancer type and over time. Multivariable logistic regression was used to estimate adjusted probabilities of receiving NGS testing. Results: Of 391 151 Medicare beneficiaries with cancer (50.6% were female; 31.8% were older than 75 years), 7.0% received non-NGS testing only, 1.2% NGS only, 0.5% both, and 91.4% no genomic testing. NGS adoption increased modestly, whereas overall genomic testing nearly tripled from 6.0% in 2016 to 16.7% in 2023. Uptake varied across cancers; beneficiaries with lung cancer had the highest NGS uptake (1.6% in 2016 vs 9.2% in 2023; P < .001), whereas beneficiaries with breast cancer showed the sharpest increase in non-NGS testing without a parallel increase in NGS. Beneficiaries with colorectal or endometrial cancer showed a moderate increase, whereas beneficiaries with prostate cancer had the lowest uptake for any genomic testing. In adjusted analyses, the largest increase was observed among beneficiaries with lung cancer (5.16 percentage points [95% CI, 4.75-5.56 percentage points]; P < .001) during the post-germline NCD phase. Conclusions and Relevance: In this cohort study of Medicare beneficiaries with cancer, genomic testing increased after NCD implementation, with increases driven by NGS among beneficiaries with lung cancer and non-NGS among beneficiaries with breast cancer. Overall, NGS uptake remained modest, highlighting persistent gaps in access to precision oncology testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.